The availability of inducible expression systems makes regulatable control of therapeutic proteins an attainable goal in gene therapy. We delivered tetracycline-inducible transgenes to the subretinal space using recombinant adenoviruses. Upon administration of doxycycline, we demonstrated reversible expression of green fluorescent protein in
Introduction
Gene delivery using viral vectors can result in long-term sustained transgene expression in the eye; [1] [2] [3] [4] however, technological improvements are required in order to move gene-based rescue into clinical practice. A key issue is the ability to modulate transgene expression. Ideally, expression must mimic endogenous patterns and levels. Tight control must be maintained both temporally and quantitatively to avoid aberrant production of protein which may alter signal transduction pathways or activate host immune responses. Moreover, certain diseases have a narrow therapeutic window, thus treatments must not only be specific, but timely. Incorporation of cell-specific regulating elements may aid in this process; however, such elements have not been identified in all ocular cell types, and those that have been identified are generally quite large, exceeding the size constraints of viral vectors with limited cargo capacities.
In order to gain control over the timing and levels of transgene expression, attempts have been made to develop inducible gene-expression systems. 5 Ideal inducible systems should be regulated by an exogenous, nontoxic, orally active compound, which does not have an effect on endogenous cellular genes. In addition, expression of the transgene should be silent in the absence of inducer as well as reversible upon its withdrawal. 5, 6 The tetracycline-responsive promoter system, based on the Tn10-specified tetracycline resistance operon of E. coli, seems to fulfill these criteria. 7 The presence (Tet-On) or absence (Tet-Off) of tetracycline serves to modulate the binding of the transactivator to the operator sequence, leading to transcriptional activation. 7, 8 Orally administered tetracyclines readily penetrate the blood-retinal barrier, thus it would seem possible to control ocular-specific transgene expression by delivery of tetracycline, or one of its analogs, to drinking water. 9 We have explored the possibility of regulating transgene expression in the retina using either a local marker (enhanced green fluorescent protein (EGFP)) or a secretable protein (human growth hormone (hGH)), following adenovirus (Ad)-mediated transgene delivery of the TetOn system to the subretinal space, the area which separates the photoreceptor outer segments from the retinal pigment epithelium (RPE). This mode of vector delivery results primarily in transduction of RPE. 1, 10 Due to the unique immune-privileged status of this site, systemic immune responses are minimized.
11 Consequently, it is theoretically possible to deliver genes to ocular cells and control them much like any other conventional drug, administered on an as-needed basis for therapeutic purposes.
Results
In vivo regulation of EGFP in the RPE The ability to infect RPE cells with the Ad-TetOn system was assessed by visualizing EGFP fluorescence, both ophthalmoscopically and histologically. Viruses carrying the Tet-On transactivator (Ad.CMV-TetOn) and the cDNA encoding EGFP linked to the tet-responsive element (Ad.TRE-EGFP) were administered to nu/nu mice via bilateral subretinal injections such that the dose of each virus was 2 × 10 9 particles per eye. In order for this system to be effective it is necessary for both viruses to infect a single ocular cell. Thus, animals receiving a single virus served as negative controls. EGFP-positive cells were not detected in these control animals at any of the analyzed time-points (data not shown).
Sixteen eyes were injected at the onset of the experiment. Four to six eyes were examined ophthalmoscopically at each time-point and two to four eyes were analyzed histologically. Figure 1 shows one representative eye at each time-point. Only one of the 16 injected eyes failed to express EGFP following oral doxycycline administration (day 23). The presence of EGFP observed ophthalmoscopically correlated to what was seen histologically. The region of the eye expressing EGFP was restricted to the site of injection; however, levels of expression varied from eye to eye according to the amount of retina exposed to virus through subretinal injection. Such variability, accounting for a range of one eighth to one third of the retina being exposed to virus, has been described previously. 12 Two days following dual Ad administration, EGFP fluorescence was not observed ( Figure 1A -day 2). With the administration of a 7 day course of doxycycline (2 mg/ml supplemented with 5% sucrose) in drinking water, transgene expression was turned on predominantly in the RPE ( Figure 1B In order to confirm EGFP induction on a transcriptional level, EGFP message was analyzed via reverse transcription polymerase chain reaction (RT-PCR) ( Figure  2 ). Immunocompetent C57BL/6 mice (n = 4 eyes) were administered virus as described above. Two days following injection one animal was killed while the other received oral doxycycline for 5 days and was then killed. Eyes were enucleated, and RNA was isolated. EGFP message (320 bp, lower arrow) was compared with ribosomal rRNA (410 bp, upper arrow), serving as an internal control. With the administration of drug, an induction of EGFP message was detected. Basal leakiness of the system was also observed, as indicated by low levels of EGFP message in the group unexposed to doxycycline.
In vivo regulation of hGH
To test the hypothesis that the RPE could serve as a site of production of a secretable protein, we administered viruses encoding the Tet-On transactivator (Ad.CMVTetOn) and the hGH genomic clone, linked to the tetresponsive element (Ad.TRE-hGH) to NCR nude mice via bilateral subretinal injections. The dose of each virus was 1 × 10 9 particles per eye. Since hGH is a small (22 kDa), biologically active, secretable protein, it readily passes through the blood-retinal barrier, allowing for fluctuations in hGH levels to be monitored in serum via ELISA.
Doxycycline was administered and eliminated from drinking water over a course of 40 days in order to regulate serum hGH levels at will (Figure 3 ). Early leakiness was observed in all animals; however, it attenuated over the course of 20 days as demonstrated by the control group (represented by the hatched line). Animals serving as the experimental group (represented by the solid line) had increased serum hGH levels when 2 mg/ml (days 7 and 23) or 0.5 mg/ml (day 38) doxycycline was administered to their drinking water. In contrast, serum hGH levels dropped to undetectable levels after control animals were maintained on water for 23 days. When drug was eliminated from the treated group, serum hGH levels consistently dropped to that of controls (days 16 and 31). Control animals were subsequently exposed to an intermediate dose of doxycycline (1 mg/ml). Serum hGH levels increased significantly, from a basal reading of 0 pg/ml (day 23) to levels Ͼ1000 pg/ml. The up-regulation of hGH levels was consistently achieved with varying concentrations of doxycycline. This induction appeared dose dependent, and the average serum hGH levels were 1868, 1195 and 327 pg/ml following treatment with 2, 1 and 0.5 mg/ml doxycyline in drinking water, respectively. A final administration of 2 mg/ml antibiotic to all animals on day 45 resulted in peak circulating hGH levels which were comparable with the first induction. Animals were maintained on drug treatment for 3 weeks. Eyes (n = 13) were then examined for hGH immunostaining and transgene expression could be detected in the RPE. Figure 4 shows a representative injected (a) and control (b) eye.
Discussion
Although gene therapy has the potential for being a powerful therapeutic tool, techniques are currently limited by the inability to modulate careful gene expression by external cues. We have demonstrated local and systemic regulation of reporter genes (EGFP and hGH respectively) following administration of the Ad-TetOn system to the subretinal space. Injection of replicationdefective Ad to this area results in transduction of nearly 100% of exposed RPE cells within 48 h of delivery, as well as occasional Muller cells. 1 The eye has many unique properties which make it especially amenable for gene therapy. It is a highly accessible organ with altered immunological properties, important considerations for easy delivery of virus and avoidance of systemic immune responses. Furthermore, only small amounts of virus are required to target the tissue. Current strategies aimed at rescuing degenerative cells in the retina include replacing missing or defective genes with wild-type genes and delaying cell death by introducing growth factors. 13 Either mode of rescue will require regulation of the gene being delivered, as underproduction may not be effective and excess may lead to cell death. For example, it is well known that overproduction of normal rhodopsin leads to photoreceptor degeneration or cellular toxicity; 14 however, lack of this protein also leads to retinal degeneration. [15] [16] [17] This suggests that there must be a critical rhodopsin level that must be maintained and cannot be exceeded. Likewise,
Figure 4 hGH immunohistochemistry. Mice were administered dual viruses (Ad.CMV-TetOn/AdTREhGH) and maintained on doxycycline (2 mg/ml) for 3 weeks before being killed. hGH immunohistochemistry was performed on paraffin sections, and detected in the RPE and occasional Muller cells of these animals (arrowheads) (a). This signal was absent in age-matched control animals which were not treated with virus or drug (b).
reports of ocular toxicity due to potentially therapeutic growth factors, such as TGF-␤ 18 and bFGF, 19 suggest that levels of these agents must also be regulated.
The results from the EGFP studies strongly suggest the possibility of specifically regulating therapeutic genes in particular retinal cell types, by harnessing the Tet-On system into a viral vector. The EGFP reporter gene provides a marker which can be identified in vivo in non-invasive fashion and then terminally in histological studies. One challenge of the EGFP variant used in these experiments is that the protein has a long half-life (Ͼ24 h). This may account for the variability between the levels of EGFP message and the high protein levels seen histologically. We also used secretable hGH as a reporter gene. The results demonstrate the ability of the RPE to secrete a therapeutic protein in a regulatable, dose-dependent manner. Interestingly, high levels of hGH were detected in the systemic circulation of the injected animals following doxycycline administration when compared with uninjected controls. This may be due to the unique property of the subretinal technique, allowing for many target cells to be transduced with both viral vectors encoding the regulatable system.
Our studies focused on the use of Ad to target RPE cells; however, it is also feasible to transduce other ocular cell types. Incorporating cell-specific promoters 3 into the transactivator, varying the mode of injection (subretinal versus intravitreal) 20 and substituting the virus harboring the cassette (Ad 1,10 versus adeno-associated virus (AAV) [2] [3] [4] versus lentivirus 21, 22 ) can dramatically change the target cell. For example, subretinal application of AAV results in efficient transduction of photoreceptor cells, while intravitreal injection of Ad efficiently targets Muller, corneal endothelium, iris pigment epithelium and trabecular meshwork cells. 23 Although basal leakiness of the Tet system should be addressed, significant quantitative differences in expression were achieved in the present study. Thus, this system proves promising in delivering therapeutic proteins in a regulated manner. Many of the genes responsible for RP have been identified; nevertheless, the mechanisms by which photoreceptor degeneration results are not known; therefore, such a system may also provide a means for elucidating these pathways, as it allows for tight control of expression and timing.
Materials and methods

Adenoviral vector construction
The Tet-On cassette was isolated from pTet-On (Clontech, Palo Alto, CA, USA) using XhoI and PvuII. The 2400 bp fragment was then blunted and subcloned into the EcoRV site of pAd.link (Institute for Human Gene Therapy Vector Core, University of Pennsylvania, Philadelphia, PA, USA) to generate Ad.CMV-TetOn.
The hGH genomic sequence was isolated from pAAV.ZG1 24 using ClaI and SpeI. The hGH fragment (1542 bp) was then blunted and subcloned into the SacII site of the pTRE response plasmid (Clontech). The resulting plasmid, designated pTRE-hGH, was digested with XhoI and HindIII to isolate a 2500 bp fragment encoding the TRE (tet-responsive element), hGH genomic clone and the SV40 polyA tail. This fragment was blunted and subcloned into the EcoRV site of pAd.link to generate Ad.TRE-hGH.
Gene Therapy
The TRE-SV40 poly A transcriptional cassette was isolated from the pTRE response plasmid using XhoI and EcoRI and subcloned into pAd.link, generating pAdTRElink. The CMVEGFP minigene was isolated from pAdCMVEGFP 25 using PvuI and EcoRI and then subcloned into the PvuI/SalI site of pAdTRElink, generating the new plasmid designated Ad.TRE-EGFP.
Adenoviral propagation and purification
Recombinant viruses were prepared as previously described. 25, 26 Animal studies Immunocompetent and nu/nu C57BL/6 (female, 5-7 weeks old; Jackson Laboratories, Bar Harbor, ME, USA) or NCR nude (female, 8-10 weeks old; Taconic Farms, Germantown, NY, USA) mice were anesthetized (AVERTIN (2,2,2-tribromoethanol); 0.5-0.6 mg/kg i.p.; Aldrich, Milwaukee, WI, USA) and dual viruses (Ad.CMV-TetOn/Ad.TRE-EGFP or Ad.CMV-TetOn/ Ad.TRE-hGH) were delivered bilaterally via a transscleral transchoroidal approach, as previously described. Following subretinal delivery of virus, rodents were administered doxycycline hydrochloride (Sigma, St Louis, MO, USA; 2 mg/ml, 1 mg/ml or 0.5 mg/ml, supplemented with 5% sucrose) in drinking water ad libitum for different predetermined times. Serum samples were obtained from animals receiving Ad.CMV-TetOn/ Ad.TRE-hGH via retro-orbital bleed. Animals were killed by carbon dioxide asphyxiation, eyes enucleated and then stored in 4% paraformaldehyde/phosphatebuffered saline for histological processing.
Ophthalmoscopy EGFP expression was monitored in vivo using ophthalmoscopy. Eyes were dilated with topical 0.5% tropicamide and indirect ophthalmoscopy was performed with a 90 diopter lens. The fundus examination was documented by photography.
Histology
Following enucleation and fixation, eyes prepared for cryosectioning were transferred to 30% sucrose in phosphate-buffered saline (4°C, overnight), and embedded in tissue freezing media (Triangle Biomedical Sciences, Durham, NC, USA). Sections (7-10 microns) were obtained and assessed for EGFP by fluorescence microscopy. True EGFP fluorescence (as opposed to autofluorescence) was assessed by comparing results after illumination with a FITC and a rhodamine (or dual) filter.
Paraffin sections were prepared for hGH immunostaining. A anti-hGH rabbit polyclonal primary antibody (1:100 dilution, Novocastra Laboratories Ltd, Newcastle, UK) and a peroxidase conjugated goat anti-rabbit secondary antibody (1:500 dilution, Ventana Medical Systems, Tucson, AZ, USA) were used.
RT-PCR
Eyes were enucleated, placed on dry ice and stored at −80°C. Total RNA was extracted using the Trizol Reagent (Life Technologies, Gaithersburg, MD, USA) and reverse transcribed with random decamers and M-MLV-RT (Moloney murine leukemia virus reverse transcriptase). PCR (step 1: 96°C, 10 min; step 2: 21 cycles (96°C, 1 min; 58°C, 1 min; 72°C, 1.5 min); step 3: 72°C, 10 min) was performed to amplify an approximately 320 bp EGFP fragment and an approximately 410 bp fragment representing total ribosomal RNA (QuantumRNA 18S Internal Standards; Ambion, Austin, TX, USA). The oligonucleotides used to generate the EGFP PCR product were 5ЈCAAGTTCAGCGTGTCCG3Ј and 5ЈTTGTGCCCC AGGATGTT3Ј. PCR products were assessed on 2% agarose gels stained with ethidium bromide, and analyzed via densitometry.
ELISA assay Sera hGH levels were determined using the hGH ELISA kit (Roche/Boehringer Mannheim, Mannheim, Germany) according to the manufacturer's protocol.
